These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12481407)

  • 1. [Do the interferons have an antifibrotic action? The internist's point of view].
    Blétry O; Somogyi A
    Rev Med Interne; 2002 Nov; 23 Suppl 4():511s-515s. PubMed ID: 12481407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in systemic sclerosis: novel therapeutic paradigms.
    Varga J
    Curr Rheumatol Rep; 2000 Dec; 2(6):481-5. PubMed ID: 11123101
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon-gamma 1b: impact of new indications (idiopathic pulmonary fibrosis).
    Aggarwal AN; Behera D
    Expert Opin Pharmacother; 2000 Dec; 1(7):1423-7. PubMed ID: 11249475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving pharmacotherapy of pulmonary fibrosis.
    Lota HK; Wells AU
    Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-steroid agents for idiopathic pulmonary fibrosis.
    Spagnolo P; Del Giovane C; Luppi F; Cerri S; Balduzzi S; Walters EH; D'Amico R; Richeldi L
    Cochrane Database Syst Rev; 2010 Sep; (9):CD003134. PubMed ID: 20824834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of systemic sclerosis with gamma-interferon.
    Hein R; Behr J; Hündgen M; Hunzelmann N; Meurer M; Braun-Falco O; Urbanski A; Krieg T
    Br J Dermatol; 1992 May; 126(5):496-501. PubMed ID: 1610690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases.
    Prior C; Haslam PL
    Clin Exp Immunol; 1992 May; 88(2):280-7. PubMed ID: 1572093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
    Wermuth PJ; Jimenez SA
    PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of antifibrotic action of interferon gamma-1b in pulmonary fibrosis.
    Ziesche R; Block LH
    Wien Klin Wochenschr; 2000 Sep; 112(18):785-90. PubMed ID: 11072666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic sclerosis: hypothesis-driven treatment strategies.
    Charles C; Clements P; Furst DE
    Lancet; 2006 May; 367(9523):1683-91. PubMed ID: 16714190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.
    Sanchez CG; Molinski SV; Gongora R; Sosulski M; Fuselier T; MacKinnon SS; Mondal D; Lasky JA
    Arthritis Rheumatol; 2018 Jan; 70(1):115-126. PubMed ID: 28940894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of complications associated with systemic sclerosis.
    Moore SC; Desantis ER
    Am J Health Syst Pharm; 2008 Feb; 65(4):315-21. PubMed ID: 18238768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
    Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
    Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(5):457-68. PubMed ID: 17147054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy for systemic sclerosis.
    Steen V
    Autoimmun Rev; 2006 Feb; 5(2):122-4. PubMed ID: 16431341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma.
    Bryckaert M; Fontenay M; Lioté F; Bellucci S; Carriou R; Tobelem G
    Ann Rheum Dis; 1994 Nov; 53(11):776-9. PubMed ID: 7826142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.